Brought to you by 
Trovagene brings in $21.4mm through public stock sale
13 Mar 2015
Executive Summary
Trovagene Inc. (tests to measure cell-free DNA in blood and urine for the diagnosis and monitoring of cancer) netted $21.4mm through a public offering of 5.1mm common shares (including the overallotment) at $4.50.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Urine-based Testing
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Trovagene brings in $21.4mm through public stock sale
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice